OmniAb Inc (OABI) Stock Forecast & Price Target

OmniAb is attractive because its Biological Intelligence platform and proprietary transgenic animal models create differentiated antibody and peptide discovery capabilities that are difficult to replicate, while its multi-year immune-repertoire datasets and OmniDeep software improve lead identification and optimization. The company’s royalty aggregation model adds a second engine of value, with more than 425 active programs, 98% carrying downstream economics, and reiterated potential milestones of over $3B, including about $340M from clinical-stage programs, which supports a path to durable, high-margin cash flow. Near-term upside is further reinforced by new product expansion through xPloration and OmniTides, expected xPloration revenue of $2M–$3M in 2026, and the Eli Lilly collaboration that brings upfront cash, up to $370M in milestones, and tiered royalties on global net sales.

OmniAb is exposed to a valuation model that depends heavily on downstream milestones and royalties, so delayed or failed approvals on partner assets would directly weaken the company’s economics. Near-term caution in biopharma capital spending could slow program adds and reduce future revenue opportunities, while AI models that generate high-performing sequences de novo could erode demand for animal-based discovery methods. The stock also faces structural risks from commoditization or patent invalidation, which would pressure partner growth, deal terms, and the durability of OmniAb’s revenue base.